Justice Department Briefing 2026-01-08
Estimated reading time: 5 minutes
1. Meeting of the Religious Liberty Commission
Sub: Justice Department
Content: The DOJ is publishing this notice to announce the sixth Federal advisory committee meeting of the Religious Liberty Commission (Commission).
2. Meeting of the Religious Liberty Commission
Sub: Justice Department
Content: The DOJ is publishing this notice to announce the fifth Federal advisory committee meeting of the Religious Liberty Commission (Commission).
3. Importer of Controlled Substances Application: Mylan Technologies Inc.
Sub: Justice Department, Drug Enforcement Administration
Content: Mylan Technologies Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
4. Importer of Controlled Substances Application: Curium US LLC
Sub: Justice Department, Drug Enforcement Administration
Content: Curium US LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
5. Importer of Controlled Substances Application: Janssen Pharmaceuticals Inc.
Sub: Justice Department, Drug Enforcement Administration
Content: Janssen Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
6. Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
Sub: Justice Department, Drug Enforcement Administration
Content: AndersonBrecon, Inc. DBA PCI Pharma Services has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication.
This article is for informational purposes only and does not constitute legal advice.
For case-specific consultation, please contact us.
Read our full Legal Disclaimer, which also includes information on translation accuracy.
